List of Excipients in Branded Drug ANAPROX

Generic Drugs Containing ANAPROX

Company	Ingredient	NDC	Excipient
DIRECT RX	naproxen sodium	61919-183	CELLULOSE, MICROCRYSTALLINE
DIRECT RX	naproxen sodium	61919-183	CROSCARMELLOSE SODIUM
DIRECT RX	naproxen sodium	61919-183	FD&C BLUE NO. 2
DIRECT RX	naproxen sodium	61919-183	FERRIC OXIDE RED
DIRECT RX	naproxen sodium	61919-183	HYPROMELLOSES

What are the Most Frequently-Used Excipients in ANAPROX?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FD&C BLUE NO. 2
1	FERRIC OXIDE RED
1	HYPROMELLOSES

Anaprox Excipient Strategy and Commercial Opportunities for Naproxen Sodium

Last updated: September 24, 2026

Anaprox is an established naproxen sodium immediate-release tablet brand, historically marketed in 275 mg and 550 mg strengths. Its commercial value is no longer based on primary patent exclusivity. The opportunity lies in reformulation, delivery convenience, OTC positioning, combination products, pediatric dosing, and manufacturing-cost optimization.

The core excipient strategy is straightforward: preserve rapid dissolution of the water-soluble naproxen sodium salt, support tablet robustness, maintain chemical stability, and avoid excipients that increase gastrointestinal or hypersensitivity concerns. The strongest commercial concepts are fast-disintegrating tablets, liquid or pediatric products, softgels, lower-dose products, and differentiated packaging rather than a conventional generic tablet.

What is Anaprox and which drug does it contain?

Anaprox contains naproxen sodium, the sodium salt of naproxen. Naproxen sodium is an NSAID used for analgesic, antipyretic, and anti-inflammatory indications. The sodium salt dissolves more rapidly than naproxen free acid, supporting earlier absorption and onset of analgesic effect.

Historical Anaprox products included:

Product	Strength	Dosage form	Active ingredient
Anaprox	275 mg	Film-coated tablet	Naproxen sodium
Anaprox DS	550 mg	Film-coated tablet	Naproxen sodium

A 275 mg naproxen sodium tablet is approximately equivalent to 250 mg naproxen, while a 550 mg tablet is approximately equivalent to 500 mg naproxen on a molar basis. The product is pharmacologically distinct from naproxen free-acid products in salt form and labeling, but both deliver naproxen systemically.

FDA labeling identifies conventional tablet excipients including microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and film-coating components such as hypromellose, polyethylene glycol, titanium dioxide, and colorants, depending on product strength and market formulation (U.S. Food and Drug Administration [FDA], 2019).

What excipients protect the Anaprox tablet formulation?

The historical formulation uses a conventional immediate-release tablet platform. Each excipient has a defined technical role.

Excipient class	Typical function in naproxen sodium tablets	Strategic relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and dissolution
Povidone	Binder	Improves granule and tablet cohesion
Magnesium stearate	Lubricant	Supports ejection from the tablet press
Hypromellose	Film former	Protects the tablet and improves swallowability
Polyethylene glycol	Plasticizer in film coating	Reduces coating brittleness
Titanium dioxide and colorants	Opacity and product identification	Supports branding and dose differentiation

The principal formulation objective is to prevent excessive tablet hardness or hydrophobic lubricant effects from slowing dissolution. Naproxen sodium is relatively water soluble compared with naproxen free acid, so the formulation does not require a complex solubilization system. The more important controls are disintegration, blend uniformity, lubrication time, compression force, and moisture exposure.

How should excipients be selected for rapid onset?

A commercial reformulator should prioritize:

1. A robust superdisintegrant system, potentially using croscarmellose sodium, crospovidone, or sodium starch glycolate.
2. Low-to-moderate lubricant concentration to avoid delayed wetting.
3. Direct compression or dry granulation if powder flow and content uniformity are adequate.
4. Controlled tablet hardness that survives packaging and transport without slowing disintegration.
5. A low-moisture process and moisture-barrier packaging.

Crospovidone may support rapid wicking and disintegration in a directly compressed product. Croscarmellose sodium can provide strong swelling and breakup performance. A dual-disintegrant design may improve robustness but could increase formulation complexity and regulatory comparability requirements.

What formulation patents protect Anaprox?

Anaprox has no meaningful modern composition-of-matter patent position. Naproxen sodium is an old active pharmaceutical ingredient, and the historical brand has long passed the period in which primary patent exclusivity would control generic entry.

The commercially relevant protection has been regulatory and brand-based rather than a durable active patent estate. Potentially relevant patent categories include:

• Immediate-release tablet formulations.
• Sustained-release or enteric-coated naproxen products.
• Combination products.
• Pediatric liquid formulations.
• Softgel and liquid-filled capsule technology.
• Manufacturing processes for particle-size control or salt conversion.
• Method-of-use claims for specific pain or inflammatory conditions.

A formulation patent would need to claim a genuine technical distinction, such as a defined dissolution profile, stability advantage, reduced tablet size, taste-masked liquid, or controlled-release system. A conventional tablet containing naproxen sodium, microcrystalline cellulose, a disintegrant, povidone, and magnesium stearate would generally provide limited patent durability and substantial obviousness exposure.

What is the Orange Book status of Anaprox?

Anaprox is associated with an old prescription NDA and is not a current high-value Orange Book exclusivity asset. The product’s commercial position is materially different from a recently approved branded NSAID with listed patents or pediatric exclusivity.

The relevant regulatory points are:

Issue	Anaprox position
FDA pathway	Historical NDA approval for naproxen sodium tablets
Current patent value	No meaningful active ingredient patent protection
Orange Book strategy	Limited value for blocking generic entry
Generic pathway	ANDA approval for naproxen sodium tablets
Paragraph IV exposure	Low strategic significance for an old, unprotected product
Commercial barrier	Substitution, supply, quality, and channel access rather than patents

FDA regulations permit ANDA applicants to rely on the reference listed drug’s safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence. For an immediate-release naproxen sodium tablet, the principal technical requirements are strength, dosage form, route, quality attributes, and bioequivalence under the applicable FDA product-specific guidance and ANDA framework (FDA, 2024a; FDA, 2024b).

When does Anaprox lose exclusivity?

Anaprox lost practical market exclusivity decades ago. The relevant loss was driven by expiration of historical patent rights, availability of generic naproxen and naproxen sodium products, and the absence of a differentiated current delivery system.

The product should therefore be evaluated as an off-patent platform rather than as a protected branded medicine. A new formulation could create fresh intellectual property only if it contains a patentable technical improvement. New use claims may offer narrower protection, but NSAID method-of-use claims face prior-art, written-description, enablement, and obviousness challenges.

Regulatory exclusivity may apply to a genuinely new formulation or indication, but a simple excipient substitution in an existing immediate-release tablet would not normally create meaningful new exclusivity.

What excipient strategies create commercial opportunities for Anaprox?

Fast-disintegrating and orally disintegrating tablets

A fast-disintegrating naproxen sodium tablet could target patients seeking rapid administration without water. The main technical challenges are the high dose, bitter or salty taste, tablet friability, and mouthfeel.

Potential strategies include:

• Porous direct-compression matrices.
• Crospovidone or croscarmellose sodium systems.
• Mannitol or isomalt for mouthfeel.
• Ion-exchange resins or polymeric taste-masking systems.
• Flavor and sweetener systems compatible with NSAID stability.
• Blister packaging to protect friable tablets.

The 550 mg dose is less suitable for a conventional orally disintegrating tablet because of tablet size and taste burden. A 275 mg product or multi-unit presentation is more practical.

Pediatric liquid and suspension products

A naproxen sodium oral suspension could address pediatric and dysphagia markets. The formulation would require:

• Uniform suspension during shelf life.
• Taste masking.
• Preservative compatibility.
• Controlled particle-size distribution.
• Redispersibility after storage.
• Accurate dosing through an oral syringe.

Naproxen sodium is more soluble than naproxen free acid, but a high-strength liquid could create taste and chemical-stability challenges. A suspension using micronized naproxen or a buffered salt system may provide better dose flexibility, although it increases development and characterization requirements.

Softgels and liquid-filled capsules

Softgels can reduce swallowing difficulty and offer a differentiated consumer presentation. A liquid-filled system may improve dose uniformity and eliminate tablet compression issues. The active must remain chemically stable in the fill vehicle, and the shell must maintain integrity across temperature and humidity conditions.

Possible fill vehicles include polyethylene glycol systems, medium-chain triglycerides, or other pharmaceutically acceptable solvents. Compatibility screening is essential because naproxen sodium is ionic and may have different solubility behavior from naproxen free acid.

Softgels create greater manufacturing complexity than tablets but may support premium pricing in OTC channels.

Gastro-resistant or modified-release formulations

Enteric-coated naproxen products could target patients seeking delayed gastric exposure, although a delayed-release system does not eliminate the systemic gastrointestinal, renal, cardiovascular, or bleeding risks associated with NSAIDs. Any such product would require careful clinical and pharmacokinetic positioning.

A sustained-release product could extend dosing intervals and reduce pill burden. The technical challenge is controlling release of a relatively high dose while maintaining dose proportionality and preventing dose dumping. Hydrophilic matrix polymers such as hypromellose may be suitable starting points, but the resulting product would require new bioequivalence and likely additional clinical justification.

How strong is the Anaprox patent estate?

The patent estate is weak as a barrier to conventional generic competition. The active ingredient is old, the immediate-release tablet technology is conventional, and the brand does not have the exclusivity profile of a recently launched medicine.

Patent strength is higher only for a genuinely differentiated product with:

• A defined dissolution or pharmacokinetic advantage.
• A novel taste-masking architecture.
• A stable high-concentration liquid.
• A validated pediatric dosing system.
• A clinically supported modified-release profile.
• A manufacturing process with measurable quality or cost benefits.

A new product should be designed around a narrow, technically defensible claim set rather than broad claims covering naproxen sodium plus ordinary pharmaceutical excipients.

What generic launch risks exist for Anaprox?

Generic competition is structurally strong. Naproxen sodium tablets are familiar to manufacturers, have established analytical methods, and use widely available excipients.

The main risks are:

Risk	Business effect
Multiple ANDA suppliers	Price compression
Low formulation complexity	Rapid supplier entry
OTC substitution	Weak brand retention
Commodity API sourcing	Limited differentiation
Retailer private-label competition	Reduced shelf visibility
NSAID safety labeling	Limits premium positioning
Manufacturing deviations	Recalls and supply disruption

A differentiated product can reduce direct price competition, but it cannot rely on the Anaprox name alone. Commercial success would require a distinct delivery benefit, strong channel strategy, or supply advantage.

Which companies are challenging Anaprox?

The relevant competitive group is not limited to one named challenger. It includes generic manufacturers of naproxen sodium tablets, OTC manufacturers selling naproxen products, private-label retailers, and branded NSAID suppliers.

Major competitive categories include:

• Generic naproxen sodium 275 mg and 550 mg tablets.
• OTC naproxen sodium products such as Aleve.
• Naproxen free-acid tablets and capsules.
• Ibuprofen products.
• Acetaminophen products.
• Prescription NSAIDs with distinct dosing or safety positioning.

The most direct competition comes from generic naproxen sodium and OTC naproxen sodium, not from patent litigation. Publicly disclosed standalone Anaprox revenue is not a reliable commercial benchmark because the product is an old brand and financial reporting generally aggregates products by company or therapeutic category.

What patent litigation and Paragraph IV issues affect Anaprox?

Anaprox is not a current high-value Paragraph IV battleground. The product’s age and generic availability reduce the commercial significance of any challenge to historical brand rights.

For a new naproxen sodium formulation, litigation risk would shift to the new formulation patents. A sponsor could face:

• Paragraph IV challenges to formulation patents.
• Obviousness attacks based on existing naproxen products.
• Written-description challenges to broad excipient claims.
• Non-infringement arguments based on different disintegrants or coating systems.
• Inter partes review or post-grant review for eligible patents.
• ANDA approval with a Section VIII statement if method-of-use claims are carved out.

A narrow patent built around measurable performance data is more defensible than a broad excipient listing without a demonstrated technical effect.

How does Anaprox compare with naproxen and other NSAIDs?

Product category	Main differentiation	Excipient opportunity	Patent position
Anaprox-style naproxen sodium tablet	Rapid-release salt form	Low-cost immediate-release platform	Weak
Naproxen free-acid tablet	Established active form	Solubility and dissolution enhancement	Weak
OTC naproxen sodium	Consumer recognition and access	Coatings, packaging, swallowability	Brand and channel driven
Ibuprofen tablet or softgel	High OTC penetration	Softgel and liquid-fill systems	Generally weak
Modified-release NSAID	Extended dosing	Matrix or coated multiparticulates	Potentially stronger if technically novel
Pediatric naproxen liquid	Dose flexibility	Taste masking and suspension stability	Potentially differentiated

Anaprox has an onset and salt-form advantage over naproxen free acid in suitable immediate-release formulations, but it does not have a durable protection advantage over generic naproxen sodium.

Key Takeaways

• Anaprox is an old naproxen sodium immediate-release tablet brand with no meaningful modern patent barrier.
• The conventional excipient platform centers on a diluent, binder, superdisintegrant, lubricant, and film coat.
• Formulation development should focus on rapid disintegration, low moisture exposure, tablet robustness, and acceptable swallowability.
• The strongest commercial opportunities are pediatric liquids, orally disintegrating tablets, softgels, lower-dose products, and carefully designed modified-release systems.
• Generic competition is intense, and conventional tablets offer limited pricing power.
• New patent value would require a measurable technical improvement, not a routine excipient substitution.
• Anaprox’s commercial opportunity is a delivery-system or channel strategy, not restoration of legacy brand exclusivity.

Frequently Asked Questions

Is Anaprox the same as Aleve?

Both contain naproxen sodium, but they are separate branded products with different historical labeling, manufacturers, packaging, and market positioning.

Can naproxen sodium be formulated as an oral solution?

It can be explored, but taste, concentration, chemical stability, and dose uniformity are major development issues. A suspension may be more practical than a true oral solution for some strengths.

Which excipient is most important for naproxen sodium tablet disintegration?

The superdisintegrant is usually the critical excipient class. Croscarmellose sodium and crospovidone are common development options, but performance depends on compression force, lubricant level, particle size, and tablet porosity.

Does a new Anaprox formulation automatically receive new patent protection?

No. A new formulation must satisfy novelty, non-obviousness, enablement, and written-description requirements. Routine substitution of one standard excipient for another is unlikely to support a strong patent position.

Is a naproxen sodium softgel commercially attractive?

It can be attractive where swallowability, premium OTC positioning, or liquid-filled delivery offers a clear consumer benefit. The business case depends on manufacturing cost, fill-material compatibility, packaging stability, and differentiation from existing OTC naproxen products.

References

1. U.S. Food and Drug Administration. (2019). Anaprox and Anaprox DS prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application process. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024c). Naproxen sodium product-specific guidance. U.S. Department of Health and Human Services.